Comments
Loading...

Aclaris Therapeutics

ACRSNASDAQ
Logo brought to you by Benzinga Data
$3.63
-0.28-7.16%
At close: -
$3.60
-0.03-0.83%
After Hours: 6:18 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$22.00
Lowest Price Target1
$1.00
Consensus Price Target1
$11.29

Aclaris Therapeutics (NASDAQ:ACRS) Stock, Analyst Ratings, Price Targets, Forecasts

Aclaris Therapeutics Inc has a consensus price target of $11.29 based on the ratings of 10 analysts. The high is $22 issued by Evercore ISI Group on October 3, 2023. The low is $1 issued by Stifel on December 18, 2023. The 3 most-recent analyst ratings were released by Leerink Partners, Jefferies, and BTIG on November 19, 2024, respectively. With an average price target of $7.33 between Leerink Partners, Jefferies, and BTIG, there's an implied 103.70% upside for Aclaris Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jul
1
Aug
1
Sep
4
Nov
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Leerink Partners
Jefferies
BTIG
Piper Sandler
Stifel

1calculated from analyst ratings

Analyst Ratings for Aclaris Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Aclaris Therapeutics (ACRS) stock?

A

The latest price target for Aclaris Therapeutics (NASDAQ:ACRS) was reported by Leerink Partners on November 19, 2024. The analyst firm set a price target for $7.00 expecting ACRS to rise to within 12 months (a possible 94.44% upside). 11 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Aclaris Therapeutics (ACRS)?

A

The latest analyst rating for Aclaris Therapeutics (NASDAQ:ACRS) was provided by Leerink Partners, and Aclaris Therapeutics upgraded their outperform rating.

Q

When was the last upgrade for Aclaris Therapeutics (ACRS)?

A

The last upgrade for Aclaris Therapeutics Inc happened on November 19, 2024 when Leerink Partners raised their price target to $7. Leerink Partners previously had a market perform for Aclaris Therapeutics Inc.

Q

When was the last downgrade for Aclaris Therapeutics (ACRS)?

A

The last downgrade for Aclaris Therapeutics Inc happened on January 22, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Aclaris Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Aclaris Therapeutics (ACRS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on November 19, 2024 so you should expect the next rating to be made available sometime around November 19, 2025.

Q

Is the Analyst Rating Aclaris Therapeutics (ACRS) correct?

A

While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a upgraded with a price target of $2.00 to $7.00. The current price Aclaris Therapeutics (ACRS) is trading at is $3.60, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch